Form 4: Enliven Therapeutics CFO Exercises Options and Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, exercised stock options and sold shares on November 27, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, executed transactions involving the company's stock on November 27, 2024.
• Hohl exercised options to acquire 5,250 shares of common stock at a price of $2.48 per share.
• Following the exercise, Hohl sold 4,250 shares at a weighted average price of $24.7795 and 1,000 shares at a weighted average price of $25.3755.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• After these transactions, Hohl directly owns 168,556 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as the transactions are part of a pre-planned trading strategy. There is no indication of any negative implications for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.

Negatives

• The sale of shares by the CFO could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• While the transactions are part of a pre-planned trading strategy, significant insider selling can sometimes create negative market sentiment.

Industry Context

This type of filing is standard for corporate insiders who execute trades in their company's stock. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Enliven Therapeutics. Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also have executives who utilize these plans.
• The reported sale prices are within the typical range for stock transactions of this nature, and the weighted average prices are consistent with market fluctuations.
• The vesting schedule of the options is also typical, with a portion vesting initially and the remainder over a period of time.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, but the pre-planned nature of the trades should mitigate any significant concerns.

Key Dates

Keywords

insider trading, stock options, Rule 10b5-1, share sale, Enliven Therapeutics, Benjamin Hohl, CFO, ELVN